- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00916994
Prospective Study for Safety and Efficacy of InSpace™ in Rotator Cuff Tear Subjects
One-arm, International, Multi-center With Competitive Recruitment, Prospective Study to Assess the Safety and Efficacy of OrthoSpace's InSpace™ in Rotator Cuff Tear Subjects Scheduled for Surgery of the Rotator Cuff
Title: One-arm, international, multi-center with competitive recruitment, prospective study to assess the safety and efficacy of OrthoSpace's InSpace™ in rotator cuff tear subjects scheduled for surgery of the rotator cuff - A pivotal study
Device: OrthoSpace's Biodegradable Implanted Balloon (InSpace)
Study population: Rotator Cuff tear subjects scheduled for arthroscopy.
Number of subjects: Up to 70 subject for data analysis.
Number of sites: At least 4 sites in Israel.
Main Inclusion criteria: Informed consent, diagnosed with Rotator Cuff tear.
Main Exclusion criteria: Former surgery on affected shoulder, sever illness, significant shoulder co morbidities.
Follow up period: 12 months. Visits at hospital before discharge at 1-2 days post implantation, 7-10 days post implantation, 3 weeks post implantation, 6 weeks post implantation, 3,6 and 12 months post implantation.
Primary goal: To assess the safety of the SpaceGuard in Rotator Cuff tear subjects.
Secondary goals: To assess the effectiveness of the SpaceGuard in the study population. The effectiveness will be assessed by terms of good positioning of the SpaceGuard and subsequent follow-up non migration, surgeon satisfaction, pain relief and time to pain relief, Range of Motion (ROM) and time to ROM with the SpaceGuard.
Primary end point: Serious Adverse Event rate related to the device and/or system complication.
Secondary end points: Surgeon dissatisfaction following the deployment of SpaceGuard, migration of the balloon shown by ultrasound/ X-ray/MRI at relevant follow-up visits, lost of ROM and pain enhancement.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Holon, Israel, 58100
- Wolfson Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older.
- Diagnosed with Rotator Cuff tear and are scheduled for surgery.
- X-Ray of treated shoulder with no unrelated pathology and imaging (ultrasound or MRI) showing Rotator Cuff tear.
- Persistent pain and functional disability for at least 4 months.
- Documented failure of conservative treatment.
Blood work up to two weeks before implantation as follow:
- Normal CBC
- Normal electrolytes (potassium, chloride, phosphorous, sodium)
- Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3
- Platelets ≥ 100,000 cells/mm3
- Hemoglobin ≥ 10.0 g/dl
- Adequate renal function, with serum creatinine ≤ 2.0 mg/dl
- Adequate liver function, with serum bilirubin < 2.0 mg/dl
- Adequate liver function with SGOT/SGPT < 2.5 x the upper normal limit
- Normal values of the PT, PTT and INR tests
- Negative for HIV and Hepatitis B or C
- Mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements
- For Woman of Child Bearing Potential (WOCBP), negative pregnancy test and willingness to use birth control during the study.
- Singed Informed Consent Form.
Exclusion Criteria:
- Evidence of significant osteoarthritis or cartilage damage in the shoulder.
- Evidence of glenohumeral instability.
- Previous surgeries of the shoulder .
- Evidence of major joint trauma, infection, or necrosis in the shoulder.
- Patients unable to provide informed consent due to language barrier or mental status.
- Patients with a major medical condition that would affect quality of life and influence the results of the study (Including, but not limited to HIV, hepatitis, active malignancy in the past 5 years, transmural MI, CVA and other impaired neurological status, CHF or unstable angina in the past 6 months).
- Patients unwilling to be followed for the duration of the study.
- Acute infection requiring intravenous antibiotics at the time of screening.
- Other shoulder pain of unknown etiology.
- Paget's disease, osteomalacia or any other metabolic bone disease.
- Severe diabetes mellitus requiring daily insulin management.
- Bleeding disorders.
- Known cognitive disorder.
- Concurrent participation in any other clinical study.
- Physician objection.
- Subjects with sign of cervical root irritation.
- Chronic lung disease
- Trauma subjects
- For WOCBP, a positive pregnancy test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SpaceGuard Balloon implantation
|
Positioning of the balloon into the subacromial space between the humerus head and the acromion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The study's primary goal is to assess the safety of the SpaceGuard and implantation procedure, in the study population. Safety of the SpaceGuard will be assessed by reporting system related adverse events.
Time Frame: 12-36 months follow-up
|
12-36 months follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eliyahu Adar, MD, Wolfson Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BP-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rotator Cuff Tear
-
Bezmialem Vakif UniversityNot yet recruitingRotator Cuff Tears | Partial Tear of Rotator CuffTurkey
-
Keele UniversityUniversity Hospitals, Leicester; Liverpool University Hospitals NHS Foundation... and other collaboratorsWithdrawnTraumatic Rotator Cuff TearUnited Kingdom
-
Borja Alcobía-Díaz MD, PhDNot yet recruiting
-
Rush University Medical CenterSmith & Nephew, Inc.CompletedRotator Cuff Tear Repair Anchors
-
University of MichiganCompletedFull Thickness Rotator Cuff Tear
-
Johannes Kepler University of LinzCompletedFull Thickness Rotator Cuff TearAustria
-
Lawson Health Research InstituteCompleted
-
Fondren Orthopedic Group L.L.P.Not yet recruitingRotator Cuff Tear Arthropathy | Massive Irreparable Rotator Cuff TearUnited States
-
Orthofix Inc.TerminatedPEMF as Adjunctive Treatment Following Surgical Repair of Full Thickness Rotator Cuff Tears (RCStim)Full-thickness Rotator Cuff TearUnited States
-
InGeneron, Inc.CompletedRotator Cuff Tear - Partial ThicknessUnited States
Clinical Trials on SpaceGuard Balloon
-
Xuanwu Hospital, BeijingRecruiting
-
Nanjing First Hospital, Nanjing Medical UniversityCompleted
-
Medtronic EndovascularCompletedPeripheral Arterial Disease (PAD)Germany
-
BioProtectCompletedProstate CancerUnited States
-
BochangFirst People's Hospital of Hangzhou; First Affiliated Hospital Xi'an Jiaotong... and other collaboratorsNot yet recruitingIntracranial Atherosclerotic Stenosis
-
Stephane CarlierBrosMed Medical Co., Ltd; University of MonsRecruiting
-
University of Toledo Health Science CampusWithdrawn
-
Universitaire Ziekenhuizen KU LeuvenUniversity Hospital, Antwerp; AZ Sint-Jan AV; Ziekenhuis Oost-Limburg; University... and other collaboratorsCompletedPercutaneous Coronary Intervention | Chronic Total Occlusion of Coronary ArteryBelgium
-
Solace Therapeutics, Inc.Terminated
-
Henry Ford Health SystemBoston Scientific CorporationWithdrawn